Zealand Pharma ASZLDPF 62 Quick Ratio is 37.17 as of Mar. 2026, which is 429% above its 10-year median of 7.02. GuruFocus rates ZLDPF with a GF Score™ of 62/100 and a GF Value™ of $1,920.24 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 1,416 Biotechnology companies, Zealand Pharma AS ranks better than 97.6% on this metric.
Zealand Pharma AS has a quick ratio of 37.17. It generally indicates good short-term financial strength.
The historical rank and industry rank for Zealand Pharma AS's Quick Ratio or its related term are showing as below:
ZLDPF'
s Quick Ratio Range Over the Past 10 Years
Min: 3.69 Med: 7.02 Max: 37.17
Current: 37.17
During the past 13 years, Zealand Pharma AS's highest Quick Ratio was 37.17. The lowest was 3.69. And the median was 7.02.
ZLDPF's Quick Ratio is ranked better than 97.6% of 1416
companies
in the Biotechnology industry
Industry Median: 3.6
vs ZLDPF: 37.17
Zealand Pharma AS (OTCPK:ZLDPF) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Zealand Pharma AS Quick Ratio Related Terms
Zealand Pharma AS Quick Ratio Historical Data
* Premium members only.
The historical data trend for Zealand Pharma AS's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Zealand Pharma AS's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zealand Pharma AS Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zealand Pharma AS's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Zealand Pharma AS's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Zealand Pharma AS's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zealand Pharma AS (ZLDPF) has a Quick Ratio of 37.17 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Zealand Pharma AS and its competitors. This is 429% above median its historical median of 7.02. Over the past decade, Zealand Pharma AS's Quick Ratio has ranged from 3.69 to 37.17. According to the industry distribution chart, Zealand Pharma AS ranks #34 out of 1416 companies in the Biotechnology industry, placing it in the top 2.4%.
Is Zealand Pharma AS's Quick Ratio too high?
Zealand Pharma AS's current Quick Ratio of 37.17 is 429% above median its 10-year median of 7.02. Over the past 10 years, this metric has ranged from a low of 3.69 to a high of 37.17. The Biotechnology industry median Quick Ratio is 3.60. Zealand Pharma AS's value of 37.17 is 932.5% above this industry median. Based on the distribution chart, Zealand Pharma AS ranks #34 out of 1416 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Zealand Pharma AS has a GF Score™ of 62/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Zealand Pharma AS's Quick Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Zealand Pharma AS ranks #34 out of 1416 companies for Quick Ratio. This places Zealand Pharma AS in the top 2% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 3.60. Zealand Pharma AS's value of 37.17 is 932.5% above this benchmark. Historically, Zealand Pharma AS's own Quick Ratio has ranged from 3.69 to 37.17 over the past decade. While the company's 10-year median is 7.02 vs. the industry median of 3.60, Zealand Pharma AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zealand Pharma AS's current Quick Ratio of 37.17 is 932.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Zealand Pharma AS and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zealand Pharma AS's current Quick Ratio is 37.17, which is 429% above median its own 10-year median of 7.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zealand Pharma AS stock overvalued right now?
Based on GuruFocus' analysis, Zealand Pharma AS (ZLDPF) is currently considered Possible Value Trap. The stock's GF Value™ is $1,920.24, compared to a current price of $42.89 — trading 97.8% below its estimated fair value. The current Quick Ratio is 37.17, which is 429% above median its 10-year median of 7.02 and 932.5% above the Biotechnology industry median of 3.60. Zealand Pharma AS's overall GF Score™ is 62/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Zealand Pharma AS (ZLDPF), the current Quick Ratio is 37.17 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zealand Pharma AS (ZLDPF) Overvalued in 2026?
Based on GuruFocus' analysis, Zealand Pharma AS stock appears to be undervalued.
The current stock price of $42.89 is trading 97.8% below its estimated GF Value™ of $1,920.24.
GuruFocus considers Zealand Pharma AS to be Possible Value Trap.
Key valuation signals for ZLDPF:
Quick Ratio: 37.17 (429% above median its 10-year median of 7.02)
GF Value™: $1,920.24 vs. price of $42.89 (97.8% below fair value)
Industry Position: 932.5% above the Biotechnology median (#34 of 1416)
No single metric tells the full story. See the ZLDPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.
62GF Score
Get the complete analysis for ZLDPF
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ZLDPF has been successfully added to your 
